Skip to main content

Table 6 Baseline characteristics (Study 2: Conventional PH and borderline PH group in pre-capillary PH)

From: Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center

Total N Conventional pre-capillry PH n Borderline pre-capillary PH p-value
Age 489 56.1  ±  15.2 22 58.2  ±  13.9 0.5342
Sex(F/M) 489 347 / 142 22 15 / 7 0.7808
mPAP(mmHg) 489 43.7  ±  11.7 22 23.0  ±  1.2  < 0.0001
PVR (WU) 489 9.2  ±  4.6 22 4.2  ±  0.9  < 0.0001
PAWP(mmHg) 489 7.5  ±  3.1 22 5.7  ±  2.9 0.0057
CO(L/min) 489 4.3  ±  1.2 22 4.2  ±  0.9 0.5689
6MWD(m) 449 360.1  ±  104.7 12 403.2  ±  11.3 0.1704
VC,% predicted 444 86.7  ±  21.2 17 86.0  ±  28.6 0.8827
FEV1.0,% predicted 444 75.8  ±  10.8 17 73.9  ±  17.3 0.4922
DLCO/VA,% predicted 420 75.8  ±  27.3 16 70.7  ±  21.8 0.4577
PaO2(mmHg) 476 64.4  ±  21.5 22 74.6  ±  14.2 0.0281
PaCO2(mmHg) 476 38.2  ±  6.1 22 41.4  ±  9.3 0.0212
PVO2(mmHg) 475 34.4  ±  4.7 22 37.1  ±  3.7 0.0087
O2 administration( +)    71(14.5%)    1(4.6%)   0.1348
AaDo2(mmHg) 475 40.3  ±  23.8 22 26.3  ±  10.3 0.0063
WHO-FC
(I/II/III/IV)
  (6/231/241/11)   (0/17/5/0)   0.0344
Vasodilators( ±) 489 301 / 188 22 5 / 17  < 0.0001
Group 1
Age 123 47.9  ±  17.8 3 51.0  ±  66.0 0.0357
Sex(F/M) 123 99 / 24 3 2 / 1 0.1417
mPAP(mmHg) 123 44.8  ±  12.0 3 23.3  ±  0.6  < 0.0001
PVR (WU) 123 9.0  ±  4.7 3 4.4  ±  0.5  < 0.0001
PAWP(mmHg) 123 7.7  ±  3.1 3 7.0  ±  1.7 0.0359
CO(L/min) 123 4.7  ±  1.5 3 3.8  ±  0.7 0.1295
6MWD(m) 95 398.0  ±  107.4 3 472.0  ±  61.5 0.2394
VC,% predicted 111 85.6  ±  16.9 3 91.4  ±  9.5 0.8324
FEV1.0,% predicted 111 79.1  ±  9.4 3 76.9  ±  9.9 0.4183
DLCO/VA,% predicted 107 73.4  ±  23.9 3 74.4  ±  12.8 0.5192
PaO2(mmHg) 121 72.6  ±  17.9 3 82.3  ±  3.6 0.0013
PaCO2(mmHg) 121 36.6  ±  5.3 3 39.3  ±  0.7 0.0072
PVO2(mmHg) 120 37.3  ±  4.8 3 39.8  ±  1.4 0.0003
O2 administration( +)    17(13.8%)     0(0%)   0.3479
AaDo2(mmHg) 121 33.9  ±  19.2 3 21.0  ±  4.4  < 0.0001
WHO-FC
(I/II/III/IV)
123   (3/79/40/1) 3   (0/3/0/0)   0.4546
Vasodilators( ±) 123 92 / 31 3 2 / 1  < 0.0001
Underlying diseases    (%)     (%)   
IPAH/HPAH/PVOD/PCH   55 44.7    - -   
CTD   38 30.9    1 33.3   
Congenital   16 13.0    1 33.3   
Portal hypertension   12 9.8    0 0.0   
drug/HIV   2 1.6    0 0.0   
unknown      1 33.3   
Group 3
Age 59 62.3  ±  13.2 9 63.3  ±  13.5 0.8404
Sex(F/M) 59 28 / 31 9 5 / 4 0.6506
mPAP(mmHg) 59 36.5  ±  11.0 9 22.4  ±  1.3 0.0003
PVR (WU) 59 7.4  ±  5.2 9 4.0  ±  0.8 0.0546
PAWP(mmHg) 59 4.5  ±  3.2 9 5.7  ±  3.7 0.12
CO(L/min) 59 4.4  ±  1.2 9 4.3  ±  1.2 0.8225
6MWD(m) 36 281.2  ±  89.5 5 317.6  ±  107.4 0.4098
VC,% predicted 52 59.8  ±  24.2 7 66.9  ±  33.5 0.4882
FEV1.0,% predicted 52 73.6  ±  17.2 7 68.6  ±  24.5 0.498
DLCO/VA,% predicted 43 42.0  ±  30.0 6 51.9  ±  18.7 0.4353
PaO2(mmHg) 53 64.4  ±  35.4 9 65.8  ±  15.6 0.9052
PaCO2(mmHg) 53 46.2  ±  9.6 9 47.0  ±  12.1 0.8248
PVO2(mmHg) 53 34.9  ±  4.0 9 35.1  ±  3.0 0.9152
O2 administration( +)    17(28.8%)     1(11.1%)   0.2265
AaDo2(mmHg) 52 31.4  ±  42.9 9 28.5  ±  13.7 0.8458
WHO-FC
(I/II/III/IV)
   (0/11/46/2)     (0/5/4/0)   0.0671
Vasodilators( ±) 59 35 / 24 9 0 / 9 0.0001
Underlying diseases    (%)     (%)   
ILD   36 61.0    4 44.4   
COPD   13 22.0    3 33.3   
BE   6 10.2    1 11.1   
Others   4 6.8    1 11.1   
Group 4
Age 301 58.2  ±  13.1 10 55.7  ±  15.2 0.5475
Sex(F/M) 301 216 / 85 10 8 / 2 0.5551
mPAP(mmHg) 301 44.7  ±  11.2 10 23.4  ±  0.7  < 0.0001
PVR (WU) 301 9.6  ±  4.4 10 4.3  ±  1.1 0.0002
PAWP(mmHg) 301 7.5  ±  3.1 10 5.3  ±  2.4 0.0269
CO(L/min) 301 4.2  ±  1 10 4.2  ±  0.6 0.8073
6MWD(m) 254 357.8  ±  99.4 4 458.5  ±  80.4 0.0449
VC,% predicted 278 92.2  ±  18.1 7 102.7  ±  16 0.1311
FEV1.0,% predicted 278 75  ±  9.3 7 78  ±  10.2 0.4101
DLCO/VA,% predicted 267 82.3  ±  24 7 85.2  ±  15.6 0.7473
PaO2(mmHg) 296 60.7  ±  18.2 10 80.1  ±  11.1 0.0009
PaCO2(mmHg) 296 37.5  ±  4.4 10 37  ±  4.2 0.7296
PVO2(mmHg) 296 33.1  ±  1.2 10 38.2  ±  3.9 0.0002
O2 administration( +)    34 (11.3%)     0(0%)   0.1248
AaDo2(mmHg) 296 44.8  ±  19.1 10 25.9  ±  8.1 0.002
WHO-FC
(I/II/III/IV)
  (3/138/153/7)     (0/9/1/0)   0.0345
Vasodilators( ±) 301 168 / 133 10 3 / 7 0.1049
PEA 301 156 / 145 10 0 / 14 0.0002
BPA 301 52 / 249 10 0 / 14 0.0536
Underlying diseases    (%)     (%)   
PE   279 92.7    9 90.0   
Pulmonary stenosis   20 6.6    1 10.0   
Others   2 0.7    0 0.0   
  1. Data are expressed as mean ± SD or n (%). mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; PAWP, pulmonary arterial wedge pressure; CO, cardiac output; 6MWD, 6-min walk distance; %VC, percent vital capacity; FEV1.0%, percent predicted forced expiratory volume in one second; %DLCO/VA, diffusing capacity of carbon monoxide by the alveolar volume; PaO2, partial pressure of arterial oxygen; PaCO2, partial pressure of arterial oxygen; PvO2, mixed venous oxygen tension; AaDO2, alveolar-arterial oxygen difference; WHO-FC, World Health Organization Functional Class; IPAH, idiopathic pulmonary hypertension; HPAH, hereditary pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; PCH, pulmonary capillary hemangiomatosis; CTD, connective tissue disease; ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; BE, bronchiectasis; PEA, pulmonary endarterectomy; PE, pulmonary embolism